|
[1]
|
Profile of People Living with HIV after 24 Weeks of Treatment with Dolutegravir in Kinshasa
Advances in Infectious Diseases,
2023
DOI:10.4236/aid.2023.134054
|
|
|
|
|
[2]
|
Virological and Molecular Profile of People Living with HIV after 24 Weeks of Treatment with Dolutegravir in Kinshasa
World Journal of AIDS,
2023
DOI:10.4236/wja.2023.134013
|
|
|
|
|
[3]
|
Profile of People Living with Human Immunodeficiency Virus Initiating Treatment in the Dolutegravir Era in Kinshasa, Democratic Republic of Congo
World Journal of AIDS,
2023
DOI:10.4236/wja.2023.133009
|
|
|
|
|
[4]
|
Virological and Molecular Profile of People Living with the Human Immunodeficiency Virus Starting Dolutegravir Based Antiretroviral Treatment in Kinshasa, Democratic Republic of Congo
World Journal of AIDS,
2023
DOI:10.4236/wja.2023.133008
|
|
|
|
|
[5]
|
Virological Profile of People Living with HIV after 12 Months of Treatment with Dolutegravir in Kinshasa
World Journal of AIDS,
2023
DOI:10.4236/wja.2023.134014
|
|
|
|
|
[6]
|
Fifteen years of the proficiency testing program for HIV-1 viral load testing laboratories in China, 2005-2019
Journal of Clinical Virology,
2021
DOI:10.1016/j.jcv.2021.104911
|
|
|
|
|
[7]
|
Involvement of the Genetic Diversity of HIV-1 in the Virological Treatment Failure of First Line Antiretroviral in Kinshasa
World Journal of AIDS,
2017
DOI:10.4236/wja.2017.71003
|
|
|
|